Background: Clinical data on the long-term safety and efficacy of infliximab on psoriatic patients who are older than 65 years are limited. Objectives: The aim is to report the long-term efficacy, safety and tolerance of infliximab in geriatric patients. Methods: This was a retrospective study conducted at the Department of Dermatology of the University of Rome Tor Vergata. Clinical data were reported at week 12, 52, 104, 208. Results: 151 charts were evaluated. A total of 27 patients were included. Range of the age was between 65 and 85 years; mean age was 73 years ±5.4; female to male ratio was 1:2; mean age of onset of psoriasis was 43 years±17. The average of treatment duration was 39 months ±27 (range 1–100). Fourteen patients suffered from plaque type psoriasis and 13 from psoriatic arthritis. At the baseline the mean PASI score was 15.6 ± 10.2. At week 12, 52, 104, and 208 the mean PASI was 2, 2.3, 1.9 and 1.8 respectively. A reduction in the mean PASI was maintained in the long-term treatment in 12 patients (p < 0.001). Conclusion: Our data suggest that long-term treatment with infliximab is effective and safe in patients over 65 years old and that IV therapy is also associated with a high compliance.

Chiricozzi, A., Pavlidis, A., Dattola, A., Bianchi, L., Chimenti, M.s., Fida, M., et al. (2016). Efficacy and safety of infliximab in psoriatic patients over the age of 65. EXPERT OPINION ON DRUG SAFETY, 15(11), 1459-1462 [10.1080/14740338.2016.1226279].

Efficacy and safety of infliximab in psoriatic patients over the age of 65

CHIRICOZZI, ANDREA;BIANCHI, LUCA;CHIMENTI, MARIA SOLE;SARACENO, ROSITA
2016

Abstract

Background: Clinical data on the long-term safety and efficacy of infliximab on psoriatic patients who are older than 65 years are limited. Objectives: The aim is to report the long-term efficacy, safety and tolerance of infliximab in geriatric patients. Methods: This was a retrospective study conducted at the Department of Dermatology of the University of Rome Tor Vergata. Clinical data were reported at week 12, 52, 104, 208. Results: 151 charts were evaluated. A total of 27 patients were included. Range of the age was between 65 and 85 years; mean age was 73 years ±5.4; female to male ratio was 1:2; mean age of onset of psoriasis was 43 years±17. The average of treatment duration was 39 months ±27 (range 1–100). Fourteen patients suffered from plaque type psoriasis and 13 from psoriatic arthritis. At the baseline the mean PASI score was 15.6 ± 10.2. At week 12, 52, 104, and 208 the mean PASI was 2, 2.3, 1.9 and 1.8 respectively. A reduction in the mean PASI was maintained in the long-term treatment in 12 patients (p < 0.001). Conclusion: Our data suggest that long-term treatment with infliximab is effective and safe in patients over 65 years old and that IV therapy is also associated with a high compliance.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - Malattie Cutanee e Veneree
English
Con Impact Factor ISI
Psoriasis; long-term; infliximab; elderly
Chiricozzi, A., Pavlidis, A., Dattola, A., Bianchi, L., Chimenti, M.s., Fida, M., et al. (2016). Efficacy and safety of infliximab in psoriatic patients over the age of 65. EXPERT OPINION ON DRUG SAFETY, 15(11), 1459-1462 [10.1080/14740338.2016.1226279].
Chiricozzi, A; Pavlidis, A; Dattola, A; Bianchi, L; Chimenti, Ms; Fida, M; Saraceno, R
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Chiricozzi - Efficacy and safety of infliximab in psoriatic patients over the age of 65.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 747.68 kB
Formato Adobe PDF
747.68 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/162517
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact